TRPX - Therapix Biosciences Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.0500
-0.2000 (-4.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.2500
Open4.2100
Bid4.0500 x 2200
Ask4.5000 x 800
Day's Range4.0500 - 4.2100
52 Week Range3.0000 - 9.3000
Volume13,723
Avg. Volume50,911
Market Cap14.163M
Beta (3Y Monthly)0.82
PE Ratio (TTM)N/A
EPS (TTM)-2.1230
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.00
Trade prices are not sourced from all markets
  • Therapix Biosciences Appoints Ambassador Ron Prosor as Executive Advisor
    PR Newswire7 days ago

    Therapix Biosciences Appoints Ambassador Ron Prosor as Executive Advisor

    TEL AVIV, Israel, March 19, 2019 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that the Company has appointed Ambassador Ron Prosor as a global growth strategy and international business development advisor. Ambassador Prosor, a seasoned Diplomat for the Israeli Ministry of Foreign Affairs and Israel's former Permanent Representative to the United Nations, will support Therapix to develop and execute its global growth strategy and international business development.

  • Top Marijuana Stocks on the NASDAQ
    Investopedia20 days ago

    Top Marijuana Stocks on the NASDAQ

    Although the majority of U.S.-based cannabis companies and many foreign ADRs trade over-the-counter, a few marijuana companies are traded on the NASDAQ. Some investors prefer stocks that are listed on the NASDAQ to other exchanges due to their increased liquidity and tighter spreads than the OTC markets.

  • Market Exclusive3 months ago

    Cannabis Stock News Weekend Roundup December 23

    Cannabis News On Dec. 20, President Trump signed the Agriculture Improvement Act of 2018 into law, legalizing hemp in the U.S. Among other things, this new law changes certain federal authorities relating to the production and marketing of hemp, defined as cannabis (Cannabis sativa L.), and derivatives of cannabis with extremely low (less than 0.3% […] The post Cannabis Stock News Weekend Roundup December 23 appeared first on Market Exclusive.

  • Therapix Biosciences Terminates FSD Acquisition Letter of Intent
    PR Newswire3 months ago

    Therapix Biosciences Terminates FSD Acquisition Letter of Intent

    TEL AVIV, Israel , Dec. 21, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (" Therapix " or the " Company ") (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing ...

  • Therapix Biosciences Provides Update Regarding FSD Acquisition
    PR Newswire3 months ago

    Therapix Biosciences Provides Update Regarding FSD Acquisition

    TEL AVIV, Israel, Dec. 11, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, is providing an update to shareholders regarding the previously announced binding letter of intent dated October 22, 2018 (the "LOI") with FSD Pharma Inc. ("FSD") (CSE:HUGE) (FSDDF) (0K9.F) for the acquisition of the Company by FSD (the "Transaction").

  • Therapix Biosciences Reports Third Quarter 2018 Financial Results and Provides Business Update
    PR Newswire4 months ago

    Therapix Biosciences Reports Third Quarter 2018 Financial Results and Provides Business Update

    TEL AVIV, Israel , Dec. 3, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on ...

  • Therapix Biosciences Clarifies Terms of Recently Issued Convertible Debenture
    PR Newswire4 months ago

    Therapix Biosciences Clarifies Terms of Recently Issued Convertible Debenture

    TEL AVIV, Israel, Nov. 29, 2018 /PRNewsire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced on November 27, 2018 that the Company has entered into a securities purchase agreement with YA II PN Ltd., a fund managed by Yorkville Advisors Global, for the sale in a private placement of up to $2.5 million in principal amount of unsecured convertible debentures (the "Debentures").

  • Therapix Biosciences Issues $1,500,000 Convertible Debenture
    PR Newswire4 months ago

    Therapix Biosciences Issues $1,500,000 Convertible Debenture

    TEL AVIV, Israel , Nov. 27, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (" Therapix " or the " Company ") (NASDAQ: TRPX) a specialty, clinical-stage pharmaceutical company focusing ...

  • InvestorPlace5 months ago

    Treat Aurora Cannabis Stock Normally at Your Own Peril

    In retrospect, it looks like Aurora Cannabis (NYSE:ACB) is following in the same unfortunate steps as DelMar Pharmaceuticals (NASDAQ:DMPI), Therapix Biosciences (NASDAQ:TRPX) and Maxar Technologies (NYSE:MAXR). Although ACB stock has only been a NYSE-listed ticker since Tuesday, it’s already down 18% since Monday’s last trade as an OTC-listed ticker, and is still pointed lower. ACB stock was already in a downtrend that technically started back on Oct. 16.

  • ACCESSWIRE5 months ago

    3 Marijuana Stocks Looking For A New Bull Trend

    CORAL GABLES, FL / ACCESSWIRE / October 24, 2018 / Many marijuana stocks took a tumble following Canada's recent cannabis industry legalization last week. Tuesday, sector stocks took another hit during ...

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: CASI Pharmaceuticals and Therapix Biosciences

    NEW YORK, NY / ACCESSWIRE / October 24, 2018 / Biotech stocks CASI Pharmaceuticals and Therapix Biosciences were both seeing big gains on acquisition news. CASI has acquired a U.S. FDA-approved abbreviated ...

  • Therapix Biosciences Signs Binding LOI to be Acquired by FSD Pharma for $48 Million, to Create Medical Cannabis Industry Innovator
    PR Newswire5 months ago

    Therapix Biosciences Signs Binding LOI to be Acquired by FSD Pharma for $48 Million, to Create Medical Cannabis Industry Innovator

    Therapix Biosciences Ltd. ("Therapix") (TRPX) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today signing a binding letter of intent (the "LOI") with FSD Pharma Inc. ("FSD") (CSE:HUGE) (FSDDF) (0K9.F), under which FSD will acquire Therapix, effective October 22, 2018 (the "Transaction"). The Transaction focuses on Therapix proprietary IP and related technology, and assets pertaining to all clinical stage pharmaceutical assets applications, excluding certain pain assets, such as the US based pain clinics. The Transaction combines two highly-complementary businesses and creates a medical cannabis industry leader focused on the research and development of advanced and innovative cannabinoid treatments.

  • Benzinga5 months ago

    Canadian Cannabis Producer To Buy Israeli Medical Cannabis Company

    FSD Pharma Inc. (OTC: FSDDF ), a Canada-based licensed producer of marijuana, reached an agreement to acquire nano-cap company  Therapix Biosciences ADR (NASDAQ: TRPX ), an Israel-based specialty clinical-stage ...

  • Market Exclusive5 months ago

    Stock Market News Daily Roundup October 23

    Tesla Inc (NASDAQ: TSLA) said it will report third-quarter earnings after the closing bell Wednesday. Shares of the automaker were down 1.23% in pre-market trade. Tesla has scheduled a conference call at 5:30 p.m. Eastern time to discuss the third quarter and outlook. Law enforcement agencies defused an explosive device found in Westchester County, New […] The post Stock Market News Daily Roundup October 23 appeared first on Market Exclusive.

  • Reuters5 months ago

    Canada's FSD Pharma to buy Israeli medical cannabis firm Therapix

    Canada's FSD Pharma Inc signed a letter of intent to acquire Israel's Therapix Biosciences Ltd for $48 million in stock, combining two complementary businesses focused on the research and development of cannabinoid treatments. Therapix shareholders will receive about 130 million class B subordinate shares of FSD Pharma, nearly 10 percent of the company, FSD said on Tuesday. FSD's shares will continue to be listed on the Canadian Securities Exchange and the Frankfurt Stock Exchange and the company intends to apply to list on Nasdaq.

  • FSD Pharma Signs Binding LOI to Acquire Therapix Biosciences, a Nasdaq Traded Pharmaceutical Company Focusing on the Development of Cannabinoid-Based Treatments to Create Medical Cannabis Industry Innovator
    CNW Group5 months ago

    FSD Pharma Signs Binding LOI to Acquire Therapix Biosciences, a Nasdaq Traded Pharmaceutical Company Focusing on the Development of Cannabinoid-Based Treatments to Create Medical Cannabis Industry Innovator

    FSD Pharma Signs Binding LOI to Acquire Therapix Biosciences, a Nasdaq Traded Pharmaceutical Company Focusing on the Development of Cannabinoid-Based Treatments to Create Medical Cannabis Industry Innovator...

  • ACCESSWIRE6 months ago

    Therapix Biosciences, Cannabis Based Drug Candidates Pipeline Review

    NEW YORK, NY / ACCESSWIRE / October 5, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Therapix Biosciences Ltd. (TRPX) is a specialty clinical-stage pharmaceutical company creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. On October 1st, TRPX shares closed at $4.57 and have since then hit an intra-day high of $7.65 (+67%). Combining PEA with THC may stimulate cannabinoid receptors, inhibit metabolic degradation, and thus increase uptake of THC.

  • ACCESSWIRE7 months ago

    Clinical Stage Marijuana Focused Biotech Stocks Trend Higher In August

    CORAL GABLES, FL / ACCESSWIRE / August 30, 2018 / Typically the stock market slows down toward the end of summer but this year that has not been the case. The markets are hitting all time highs and one of the top sectors leading the charge: biotechnology. Big pharma is weighing in on clinical stage companies as smaller biotechnology companies are benefiting big after multi-million dollar strategic investments and a strong M&A climate.

  • Therapix Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update
    PR Newswire7 months ago

    Therapix Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update

    TEL AVIV, Israel , Aug. 20, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, ...

  • PR Newswire8 months ago

    Therapix Biosciences Announces Positive Data From Recent Pre-clinical Studies for its Drug Candidate THX-160 for Treatment of Pain

    TEL AVIV, Israel, July 17, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today positive results in its pre-clinical studies evaluating THX-160, a novel pharmaceutical CB2 Receptor agonist for the treatment of pain. This innovative CB2 receptor agonist, which was found to be superior out of two candidates the Company had tested, was synthesized by Raphael Mechoulam, Ph.D., Professor of Medicinal Chemistry at the Hebrew University, and a member of the Therapix Scientific Advisory Board. To date, prescription opioids are considered to be the most effective treatment for moderate-to-severe pain, but their abuse has been identified by the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) as a significant public health issue.

  • Therapix Biosciences Signs Term Sheet for the Transfer of Non-Pain Cannabinoid-Based Drug Pipeline Assets to Cure Pharmaceutical
    PR Newswire8 months ago

    Therapix Biosciences Signs Term Sheet for the Transfer of Non-Pain Cannabinoid-Based Drug Pipeline Assets to Cure Pharmaceutical

    The term sheet entered into is non-binding and subject to ongoing due diligence and the entry into of definitive agreements and the fulfillment of certain agreed conditions. Pursuant to the term sheet, the parties propose that Therapix will receive newly issued shares in CURE in exchange for the assets, and Therapix will as a result become a significant shareholder in CURE.

  • Therapix Biosciences Updates Regarding TASE Delisting
    PR Newswire9 months ago

    Therapix Biosciences Updates Regarding TASE Delisting

    In coordination with the TASE, the Shares will be delisted from the TASE on August 9, 2018 ("Delisting Date"), and until the Delisting Date, Therapix's Shares will continue to be traded on the TASE. The last trading day in which the Shares are to be traded on TASE will be August 7, 2018.

  • Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome
    PR Newswire9 months ago

    Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome

    TEL AVIV, Israel, June 11, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announces sponsorship of the 11th  European Society for the Study of Tourette Syndrome (ESSTS) conference, in Copenhagen Denmark, on June 13th until June 15th, as part of the Company's strategy to develop therapy for Tourette's patients and to support the Tourette's community.